Tarsus COO sells 4,564 shares at $85 each
Tarsus Pharmaceuticals’ chief operating officer reported a pre-planned open-market sale of 4,564 shares and now directly holds 78,532 shares of TARS common stock.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Operating Officer Neervannan Seshadri sold 4,564 shares of common stock on September 4, 2026 at $85.00 per share in an open-market transaction effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following this sale, he directly holds 78,532 shares and is also reported with an indirect balance of 475 shares related to his daughter, for which beneficial ownership is disclaimed.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 4,564 shares
Net Sell
2 txns
Insider
Neervannan Seshadri
Role
Chief Operating Officer
Sold
4,564 shs ($388K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 4,564 | $85.00 | $388K |
| holding | Common Stock F3 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 78,532 shares (Direct);
Common Stock — 475 shares (Indirect, By daughter)
Footnotes (3)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
- F3. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Key Figures
Shares sold: 4,564 shares
Sale price per share: $85.00 per share
Direct holdings after transaction: 78,532 shares
+3 more
6 metrics
Shares sold
4,564 shares
Common stock sale on September 4, 2026
Sale price per share
$85.00 per share
Common stock sale on September 4, 2026
Direct holdings after transaction
78,532 shares
Common stock directly held by COO after sale
Indirect holdings (daughter)
475 shares
Held by daughter; beneficial ownership disclaimed
Shares via Employee Stock Purchase Plan
305 shares
Acquired under ESPP on June 30, 2026; included in direct holdings
Net shares sold in filing
4,564 shares
Net of reported buy and sell transactions in this Form 4
Key Terms
Rule 10b5-1 trading plan, Employee Stock Purchase Plan, beneficial ownership, Section 16
4 terms
Rule 10b5-1 trading plan regulatory
"sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of the securities held by his daughter"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of the securities for purposes of Section 16 or for any other purposes"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transaction did TARS report for Chief Operating Officer Neervannan Seshadri?
Neervannan Seshadri reported a sale of 4,564 shares of Tarsus Pharmaceuticals common stock on September 4, 2026 at $85.00 per share in an open-market or private transaction under a Rule 10b5-1 trading plan.
Was the TARS insider sale made under a Rule 10b5-1 trading plan?
Yes. The filing states the sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by Neervannan Seshadri on November 13, 2025, and the plan status box is affirmed for this Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
